Small Molecule Cocktail for iPSC Reprogramming Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) face challenges such as context-dependent reprogramming conditions and the technical difficulties of high throughput screening, especially when reducing the number of exogenous transcription factors.
Innovation Solution
A composition comprising an induced mammalian pluripotent stem cell (iPSC) and a cell culture medium that includes a small molecule promoting glycolytic metabolism or a histone deacetylase (HDAC) inhibitor, along with a TGFβ receptor/ALK5 inhibitor and a MEK inhibitor, which enhances reprogramming efficiency when contacting non-pluripotent mammalian cells with exogenous polynucleotides encoding Oct4 and Klf polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If the number of exogenous transcription factors is reduced to improve safety and simplify the reprogramming process, then the safety and simplicity are improved, but the reprogramming efficiency and speed decrease exponentially
Solution Approach 1:
The patent introduces small molecules as intermediary agents that mediate the reprogramming process. These molecules (metformin, sodium butyrate, PD0325901, A-83-01) act as chemical mediators that enhance the activity of reduced transcription factor combinations, thereby maintaining reprogramming efficiency while using fewer genetic factors. The small molecules bridge the gap between reduced genetic manipulation and maintained efficiency.
Solution Approach 2:
The patent changes the chemical and metabolic parameters of the reprogramming system by introducing small molecules that modify cellular metabolism (metformin affecting glycolysis, sodium butyrate affecting histone deacetylation) and signaling pathways (PD0325901 affecting MAPK pathway, A-83-01 affecting TGF-beta pathway). These parameter changes create a cellular environment that supports efficient reprogramming with minimal transcription factors.
2Manufacturing precision
If high throughput screening is performed to identify optimal reprogramming conditions, then the reprogramming conditions can be optimized, but the technical difficulty and complexity increase
Solution Approach 1:
The patent applies partial action by using a predefined, limited set of small molecules with known biological activities rather than performing exhaustive high-throughput screening of all possible compounds. This selective approach tests specific molecules (metformin, sodium butyrate, PD0325901, A-83-01) that target key metabolic and signaling pathways, achieving effective optimization without the complexity of comprehensive screening.
Solution Approach 2:
The patent employs preliminary action by pre-selecting small molecules based on their known effects on cellular metabolism and signaling pathways before applying them to the reprogramming process. This pre-screening of candidates with established mechanisms of action simplifies the overall screening process and reduces the need for complex high-throughput methodologies.
3Reliability
If context-dependent reprogramming conditions are used to improve effectiveness for specific cell types, then the reprogramming effectiveness is improved, but the adaptability to different cell types decreases
Solution Approach 1:
The patent achieves universality by developing a reprogramming protocol using small molecules that can be applied across different cell types. The selected small molecules target fundamental cellular pathways (glycolysis, histone deacetylation, MAPK signaling, TGF-beta signaling) that are conserved across cell types, making the protocol broadly applicable while maintaining effectiveness for each specific cell type.
Solution Approach 2:
The patent applies local quality by allowing customization of the small molecule cocktail for specific cell types while maintaining a core set of molecules. The protocol can be adapted by adjusting the presence, absence, or concentration of specific molecules (metformin, sodium butyrate, PD0325901, A-83-01) to optimize for particular cell types, thereby achieving both effectiveness and adaptability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described composition significantly improves the efficiency of iPSC generation by facilitating metabolic reprogramming and reducing the reliance on genetic manipulations, making the process more accessible and efficient.
Implementation Method 1
a small molecule that promotes glycolytic metabolism
Implementation Method 2
a histone deacetylase (HDAC) inhibitor
Data Source
Figure 1(a)~1(e)
Figure 2(a)~2(f)
Figure 3(a)~3(f)
AI summary
The present invention provides for methods, compositions, and kits for producing an induced pluripotent stem cell from a non-pluripotent mammalian cell using a 3'-phosphoinositide-dependent kinase-1 (PDK1) activator or a compound that promotes glycolytic metabolism as well as other small molecules.